Trial Profile

Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On Demand Treatment and Control of Bleeding Episodes in Subjects With Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Marzeptacog alfa (Primary) ; Eptacog alfa; Factor VIII inhibitor bypassing fraction
Indications Haemophilia A; Haemophilia B
Focus Registrational; Therapeutic Use
Acronyms Crimson-1
Sponsors Catalyst Biosciences

08 Dec 2021 This trial has been discontinued in Hungary (End Date: 15 Nov 2021), according to European Clinical Trials Database record.
04 Dec 2021 This trial has been discontinued in Poland according to European Clinical Trials Database record.
04 Dec 2021 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com